Star Therapeutics Secures $125M Series D to Advance Von Willebrand Disease Drug VGA039 Through Phase 3 Testing

Star Therapeutics (搜索)搜索该词条 has secured $125 million in Series D venture funding to propel its experimental Von Willebrand disease (搜索)搜索该疾病 drug VGA039查看药品详情 through Phase 3 clinical testing, marking a significant milestone for the biotech company's lead program targeting the most common bleeding disorder.

The funding round was co-led by Sanofi Ventures (搜索)搜索该公司 and Viking Global Investors (搜索)搜索该词条, with participation from 18 total investors. According to CEO and founder Adam Rosenthal, the capital will support the company's transition from a "hub-and-spoke" biotech model to focus primarily on VGA039查看药品详情, which has advanced from preclinical development to Phase 3 trials.

Addressing an Underserved Market

Von Willebrand disease (搜索)搜索该疾病 affects up to 1% of the U.S. population according to the Centers for Disease Control and Prevention, making it the most common bleeding disorder. Like hemophilia (搜索)搜索该疾病, the condition prevents blood from clotting properly, leading to frequent bleeding episodes that can "be really severe and disruptive to daily life," Rosenthal explained.

Despite its prevalence, innovation in Von Willebrand disease (搜索)搜索该疾病 has lagged behind hemophilia (搜索)搜索该疾病 treatment advances. The condition is still largely managed with replacement clotting factors requiring frequent infusions or injections, while hemophilia has seen dramatic improvements with more convenient, longer-lasting preventive therapies.

"There hasn't been any innovation because there hasn't been that recognition of the disease burden and the market potential, and I think now that is starting to change," Rosenthal said.

Competitive Landscape Evolving

The treatment landscape is beginning to shift, however. The Food and Drug Administration expanded the use of a Takeda (搜索)搜索该公司 drug for Von Willebrand disease (搜索)搜索该疾病 in September. Roche查看公司主页's hemophilia (搜索)搜索该疾病 drug Hemlibra查看药品详情 is also in advanced testing for the condition, while privately held Hemab Therapeutics (搜索)搜索该词条 has a therapy in early development.

Star aims for VGA039查看药品详情 to become for Von Willebrand disease (搜索)搜索该疾病 what Hemlibra查看药品详情—one of Roche查看公司主页's best-selling drugs—is for hemophilia (搜索)搜索该疾病. Like Hemlibra, VGA039 is a preventive antibody drug designed to prevent bleeding episodes for longer periods than available therapies through subcutaneous injection.

Novel Mechanism of Action

VGA039查看药品详情 targets protein S查看药品详情, which boosts generation of the blood-clotting enzyme thrombin查看药品详情. This mechanism potentially differentiates it from competitors, as the drug might be effective regardless of Von Willebrand disease (搜索)搜索该疾病 type.

"We can treat all types of patients, and all types of bleeds," Rosenthal said. "We're still in generation 1.0 and we're hoping to leapfrog all that incremental innovation and go straight to a subcutaneous therapy."

Clinical Progress and Future Plans

Star presented interim results from an early-stage study at the American Society of Hematology meeting last year, which "got the attention of a lot of investors," according to Rosenthal. The company launched its Phase 3 trial in September and is exploring VGA039查看药品详情's potential in other blood disorders, though specifics haven't been disclosed.

The company maintains flexibility regarding commercialization strategy, remaining open to independent market entry or pharmaceutical partnerships. An initial public offering hasn't been ruled out either.

"It's one of those rare circumstances where the market potential is so big, but the spend to get to market is actually quite small," Rosenthal noted. "It's something that an independent biotech can very easily do on their own."

In announcing the financing, Sanofi Ventures (搜索)搜索该公司 managing director Jason Hafler called VGA039查看药品详情 "a compelling opportunity," reflecting growing investor confidence in the Von Willebrand disease (搜索)搜索该疾病 treatment space.